Pharmafile Logo
Pharmafocus logo
Advanced Search

AbbVie

Showing 15 posts of 235 posts found.

Genmab to submit FDA application for lymphoma therapy

May 2, 2025
Research and Development AbbVie, Biologics License Application, FDA, Genmab, Oncology, epcoritamab, lymphoma, therapeutics

Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) …

News
bowel_cancer_screening

The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis

August 29, 2024
Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis

The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …

News
brainss

Abbvie acquires Cerevel Therapeutics

August 2, 2024
Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia

Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …

News

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024
Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

News

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024
Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd

AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …

News

AbbVie initiates phase 3 multiple myeloma trial

June 6, 2024
Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma

AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …

News

AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC

May 31, 2024
Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

News

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024
Research and Development AbbVie, Pharmacy, R&D, facility

AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The …

News

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024
Research and Development AbbVie, Immunology, Medincell, collaboration

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation …

News

AbbVie to acquire Landos Biopharma for approximately $137.5m

March 26, 2024
Business Services AbbVie, Landos Biopharma, Pharmacy, acquisition

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under which AbbVie will acquire Landos …

News

AbbVie and Tentarix collaborate on oncology and immunology treatments

February 23, 2024
Research and Development AbbVie, Oncology, collaboration, immunology

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …

News

NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL

February 1, 2024
Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …

News

AbbVie invests $223m in Singapore manufacturing site

January 26, 2024
Manufacturing and Production AbbVie, Pharmacy, Singapore, manufacturing

AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing facility. This will create more …

News

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023
Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition

AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …

News

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023
Sales and Marketing AbbVie, Oncology, acquisition

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026